Alnylam Pharmaceuticals, Inc.

Equities

ALNY

US02043Q1076

Real-time Estimate Cboe BZX Other stock markets 16:35:05 20/04/2026 BST			5-day change	1st Jan Change
310.62 ^USD	+0.31%		-6.30%	-21.53%

04-06	BioCryst Pharmaceuticals, Inc. Appoints Sandeep M. Menon As Chief Research And Development Officer	CI
03-30	Alnylam Pharmaceuticals Announces New Data Supporting Benefits of Vutrisiran in Attr-Cm and Potential of Zilebesiran for Hypertension Management	CI

Transcript : Alnylam Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 09

Published on 06/09/2025 at 03:35 pm BST - Modified on 07/08/2025 at 12:01 am BST

S&P Capital IQ

Presenter Speech
Salveen Richter (Analysts)

Great. Good morning, everyone. Thank you so much for joining us. I'm Salveen Richter, biotechnology analyst at Goldman Sachs, and we're really pleased to be

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Alnylam Pharmaceuticals, Inc.

04-06	BioCryst Pharmaceuticals, Inc. Appoints Sandeep M. Menon As Chief Research And Development Officer	CI
03-30	Alnylam Pharmaceuticals Announces New Data Supporting Benefits of Vutrisiran in Attr-Cm and Potential of Zilebesiran for Hypertension Management	CI
03-24	Alnylam Pharmaceuticals, Inc. - Special Call
03-24	Alnylam Pharmaceuticals, Inc. Advances ATTR-CM Care with Strategic Collaboration and AI-Enabled Pathways	CI
03-24	Alnylam Pharmaceuticals, Viz.ai Collaborate on AI-Enabled Detection of Transthyretin Amyloidosis	MT
03-05	Tenaya Therapeutics and Alnylam Pharmaceuticals Enter Research Collaboration Agreement	CI
03-05	Tenaya Therapeutics inks $1.13 billion deal with Alnylam for heart-disease treatments	RE
03-05	Tenaya Therapeutics Signs Potential $1.13 Billion Deal With Alnylam	MT
03-05	Tenaya Therapeutics enters into research collaboration with Alnylam Pharmaceuticals to identify and validate novel genetic targets for cardiovascular disease therapeutics	RE
03-05	Alnylam Pharmaceuticals Insider Sold Shares Worth $2,227,698, According to a Recent SEC Filing	MT
03-03	Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute	RE
03-02	Alnylam Pharmaceuticals, Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-02-2026 09:10 AM
03-02	Alnylam Pharmaceuticals receives positive recommendation from Canada's drug agency for public reimbursement of Amvuttra	RE
03-02	Intellia gets FDA nod to resume second gene therapy trial after safety pause	RE
02-18	Alnylam Pharmaceuticals Insider Sold Shares Worth $1,284,980, According to a Recent SEC Filing	MT